MedDataX Logo

Relationship Between the Clinical Pharmacist & Antibiotic Use by Using the Electronic Program

NCT ID: NCT05002647

Last Updated: 2024-12-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

2601 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-09-15

Study Completion Date

2022-03-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A retrospective cohort study to explore the association between clinical pharmacists' interventions and antibiotic consumption through the use of the medical electronic reports and to identify mortality and cost savings in hospital infectious disease.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The role of clinical pharmacist includes :

1. a check of suitable selection and dosing of antimicrobials according to the diagnosis, type of infection, antimicrobial cultures as possible, comorbidities of patients (renal or hepatic function, etc), adverse effect, and drug interaction with other drugs.
2. Documentation of the clinical intervention, cost-saving, adverse effect,, antimicrobial culture and antimicrobial consumption on the electronic program (CPC "clinical patient care").
3. The clinical pharmacist inspector reviews the data recorded on CPC.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Clinical Pharmacists Electronic Medical Record

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

clinical pharmacist antibiotic consumption antibiotic use cost-saving

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

exposure group

Data from electronic clinical pharmacist records of two infectious disease hospitals

NO intervention

Intervention Type OTHER

There is no intervention

Non-exposure group A

Data from medical records of the hospital with no clinical pharmacy.

NO intervention

Intervention Type OTHER

There is no intervention

Non-exposure group B

Data from a medical record of the hospital with clinical pharmacy, but the department did not cover by the clinical pharmacy

NO intervention

Intervention Type OTHER

There is no intervention

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

NO intervention

There is no intervention

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* All inpatient with infectious disease (disorders caused by organisms as (bacteria, viruses, fungi, or parasites).

Exclusion Criteria

* Any other cause of hospital admission other than infectious disease.
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Ministry of Health and Population, Egypt

OTHER_GOV

Sponsor Role collaborator

Alexandria University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Amira zidane

Role: PRINCIPAL_INVESTIGATOR

Ministry of Health and Population, Egypt

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Ministers of health

Alexandria, , Egypt

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Egypt

References

Explore related publications, articles, or registry entries linked to this study.

Karakonstantis S, Kalemaki D. Antimicrobial overuse and misuse in the community in Greece and link to antimicrobial resistance using methicillin-resistant S. aureus as an example. J Infect Public Health. 2019 Jul-Aug;12(4):460-464. doi: 10.1016/j.jiph.2019.03.017. Epub 2019 Apr 10.

Reference Type BACKGROUND
PMID: 30981652 (View on PubMed)

Dyar OJ, Huttner B, Schouten J, Pulcini C; ESGAP (ESCMID Study Group for Antimicrobial stewardshiP). What is antimicrobial stewardship? Clin Microbiol Infect. 2017 Nov;23(11):793-798. doi: 10.1016/j.cmi.2017.08.026. Epub 2017 Sep 4.

Reference Type BACKGROUND
PMID: 28882725 (View on PubMed)

Ourghanlian C, Lapidus N, Antignac M, Fernandez C, Dumartin C, Hindlet P. Pharmacists' role in antimicrobial stewardship and relationship with antibiotic consumption in hospitals: An observational multicentre study. J Glob Antimicrob Resist. 2020 Mar;20:131-134. doi: 10.1016/j.jgar.2019.07.009. Epub 2019 Jul 16.

Reference Type BACKGROUND
PMID: 31323427 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

14-2021/13

Identifier Type: -

Identifier Source: org_study_id